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Abstract
Background: Antibodies (Abs) produced during HIV-1 infection rarely neutralize a broad range of viral isolates; only eight
broadly-neutralizing (bNt) monoclonal (M)Abs have been isolated. Yet, to be effective, an HIV-1 vaccine may have to elicit
the essential features of these MAbs. The V genes of all of these bNt MAbs are highly somatically mutated, and the VH genes
of five of them encode a long ($20 aa) third complementarity-determining region (CDR-H3). This led us to question
whether long CDR-H3s and high levels of somatic mutation (SM) are a preferred feature of anti-HIV bNt MAbs, or if other
adaptive immune responses elicit them in general.
Methodology and Principal Findings: We assembled a VH-gene sequence database from over 700 human MAbs of known
antigen specificity isolated from chronic (viral) infections (ChI), acute (bacterial and viral) infections (AcI), and systemic
autoimmune diseases (SAD), and compared their CDR-H3 length, number of SMs and germline VH-gene usage. We found
that anti-HIV Abs, regardless of their neutralization breadth, tended to have long CDR-H3s and high numbers of SMs.
However, these features were also common among Abs associated with other chronic viral infections. In contrast, Abs from
acute viral infections (but not bacterial infections) tended to have relatively short CDR-H3s and a low number of SMs,
whereas SAD Abs were generally intermediate in CDR-H3 length and number of SMs. Analysis of VH gene usage showed
that ChI Abs also tended to favor distal germline VH-genes (particularly VH1-69), especially in Abs bearing long CDR-H3s.
Conclusions and Significance: The striking difference between the Abs produced during chronic vs. acute viral infection
suggests that Abs bearing long CDR-H3s, high levels of SM and VH1-69 gene usage may be preferentially selected during
persistent infection.
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Introduction
A highly diverse repertoire of antibodies (Abs) is a prerequisite
for the adaptive immune system to recognize a vast array of
antigens (Ags) and distinguish self from non-self. Three processes
contribute to the production of this diverse repertoire: (i) somatic
recombination of germline V, D and J genes, (ii) addition and
deletion of nucleotides at the V-D, D-J, and V-J junctions, and (iii)
somatic hypermutation after Ag stimulation [1,2]. The third
complementarity-determining region of the Ab heavy chain
(CDR-H3) is encoded by the DH gene, parts of the VH and JH
genes, and nucleotides added at the junctions between these; it is
the most variable region in the Ab, and typically is central to
contact with cognate Ag [3].
A major goal for an HIV vaccine is to elicit Abs that neutralize a
broad range of HIV-1 primary isolates. To this end, efforts have
been made to identify and use broadly (b) neutralizing (Nt)
monoclonal (M) Abs with this activity for epitope-targeted vaccine
design [4]. The bNt MAbs identified so far are rare and most of
them bear unusually long CDR-H3s. Despite intensive effort, only
eight bNt MAbs have been discovered (b12, 2F5, 4E10, 2G12,
447-52D, PG9/PG16, VRC01/02, and HJ16 [5,6,7,8,9]; 5 of
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numbering system). Consistent with this, most HIV-1-infected
individuals produce strong strain-specific Nt Ab responses against
HIV-1 envelope (Env) soon after initial infection; yet rarely do
they develop broad neutralization [10,11], and then only after a
year or more [12].
While high levels of SM have been noted for all bNt MAbs,
starting with Kunert et al. [13], a number of authors have
proposed a connection between the length of the CDR-H3
region, and the broad neutralization of these MAbs [5,7,14,
15,16,17,18,19,20,21]. Mutagenesis experiments and/or X-ray
crystal structures of Fab bound to protein or peptide Ag have
implicated their CDR-H3s as being required for neutralization:
b12 [15,22], 2F5 [16,23,24], 447-52D [17], and 4E10 [18,25].
This has been observed even in cases in which CDR-H3 appears
to make minimal or no contact with envelope protein Ag [16,23].
It has been speculated that in these cases, CDR-H3 may contact
other sites on HIV-1, such as the viral membrane
[16,18,19,20,24,25,26]. Nevertheless, it is not clear whether long
CDR-H3s are required, in general, for broad neutralization;
certainly the exceptions, MAbs 2G12 and VRC01/02, disprove
this as an absolute rule for broad Nt activity.
While it is generally acknowledged that high levels of SM are
produced by T-cell driven processes in germinal centers, the
conditions under which long CDR-H3 Abs appear in adaptive
immune responses are less well understood, and this could help
explain the origin of bNt Abs during HIV infection. Importantly,
the long CDR-H3s have been associated with anti-protein Abs
[27] and anti-viral Abs [28]. Long CDR-H3s found among
polyreactive natural Abs [29,30] and autoreactive Abs produced
by naı ¨ve B cells in SLE patients [31] do not carry SMs; yet, those
found among the memory B cells in healthy people do [32].
However, analyses to directly associate different types of adaptive
immune response with CDR-H3 length have not been reported.
Our purpose was to identify the circumstances under which Abs
bearing some of the features of bNt MAbs (viz., long CDR-H3s
and high levels of SM) appear during adaptive immune responses
in humans.
As an initial approach, we examined heavy chain variable (VH)
genes expressed by individuals undergoing Ag-specific immune
responses, by compiling a database of expressed human VH genes
of MAbs for which the Ag specificity of the MAb was known. The
MAbs were taken from individuals with chronic infections (ChI),
acute infections (AcI), or following immunization (included with
AcI MAbs), and systemic autoimmune diseases (SAD). CDR-H3
length, level of SM, and VH-gene usage were compared among
MAbs with specificity against self vs. non-self Ag, with specificity
against protein vs. non-protein Ag, and/or from different
conditions (ChI MAbs, SAD MAbs and AcI MAbs).
Both long CDR-H3s and SMs were strongly associated with
protein Ag. Long CDR-H3s were at their highest frequency
among ChI MAbs, and less so among SAD and AcI MAbs,
whereas SMs were more prevalent in ChI and SAD anti-protein
Abs and greatly reduced among anti-protein AcI Abs. Both ChI
and AcI Abs tended to use distal VH genes; the use of VH1-69 was
especially high among anti-HIV Abs, and was associated with high
levels of SM and long CDR-H3s. The picture emerging from this
analysis is that Abs bearing high numbers of SMs, long CDR-H3s
and the distal gene VH1-69 appear to be selected in chronic vs.
acute viral infections. Thus different biological processes, and
perhaps different B-cell subsets, such as marginal zone vs.
conventional B2 B cells [33,34], (see Baumgarth [35] for review)
could be involved in the earlier vs. later stages of viral infection,
respectively.
Results
CDR-H3 length of expressed VH genes in adaptive Ab
responses
Table 1 summarizes the analysis of expressed VH genes for
several MAb categories with regard to CDR-H3 length, number of
SMs relative to the predicted germline VH gene, and the distance
in the IgH locus between an Ab’s germline VH gene and the VH6-
1 gene, the VH gene closest to the DH region. As expected, the bNt
HIV MAbs had the longest CDR-H3s with an average length of
20.9 aa. Fig. 1 compares the CDR-H3 length distributions for the
bNt HIV MAbs, the non-bNt HIV MAbs (i.e., excluding the bNt
HIV MAbs), and the remaining ChI MAbs (excluding all HIV
MAbs). It shows that both the bNt and non-bNt HIV MAbs have
long CDR-H3s; the difference between these two MAb groups was
only marginally significant (Table 1A; unadjusted p = 0.0501),
and not significant compared to the Bonferroni corrected value of
0.0018. Thus, CDR-H3 length does not appear to be restricted to
broad neutralization. In addition, the CDR-H3s of all of the anti-
protein HIV MAbs (mean 17.8 aa) were not significantly longer
than those of non-HIV ChI MAbs (16.5 aa). Although our data set
has only 34 non-HIV ChI MAbs, 12 of these have CDR-H3s of 19
aa or longer (Fig. 1), placing them in the upper quartile of the 427
Ag-specific MAbs. Thus, long CDR-H3s were associated with all
types of ChI MAb, including the anti-HIV MAbs.
Fig. 2 shows the distribution CDR-H3 length for anti-HIV
MAbs, partitioned according the region of Env bound; CDR-H3
length was longest for MAbs against the CD4i site (19.6 aa),
intermediate for those against the V3 loop (18.5 aa) and CD4bs
(18.3 aa), and shortest for the anti-gp41 MAbs (15.9 aa). These
distributions were significantly different (x
2 test, p,0.05, PROC
FREQ, SAS), indicating that, while the anti-HIV MAbs as a whole
bear long CDR-H3s, epitope specificity also shapes CDR-H3
length.
The observation that long CDR-H3s are associated with
chronic viral infections in general led us to compare MAbs from
such infections to those from other immune responses, namely
SAD and AcI. Categorization of MAbs by these types of immune
response showed that the average length of the ChI MAbs (17.6
aa, Table 1B and Fig. 3A) was most different from the AcI MAbs
(14.7 aa), with the SAD MAbs being intermediate (15.1 aa). This
trend, of the AcI MAbs being the most different from the ChI
MAbs, persisted when the categories were further divided into Abs
against protein vs. non-protein Ags (Fig. 3B and Table 1B). For
example, among anti-protein MAbs, those from the ChI group
had significantly longer CDR-H3s than did those from the AcI or
SAD groups (p,0.0001). As virtually all of the ChI Abs (except
bNt MAb 2G12) and all of the anti-protein AcI Abs are anti-viral,
it is striking that a large difference in CDR-H3 length exists
between the Abs elicited by the two types of viral infection. In
addition, anti-protein MAbs had significantly longer CDR-H3s
than MAbs against non-protein Ags (p,0.0001, Table 1C), even
with the Bonferroni correction; while the difference between self
and non-self Abs was not as great (p,0.005, not significant with
the Bonferroni correction). Thus autoimmune status (self vs. non-
self) had a much lower effect on CDR-H3 length than did protein
vs. non-protein Ag.
SM of expressed VH genes in adaptive Ab responses
That long CDR-H3s were found mainly among anti-protein
Abs suggests that Abs with long CDR-H3s are selected by protein
Ag, and hence, by T-cell-driven processes; such responses typically
occur in germinal centers and involve SMs introduced by
activation-induced cytidine deaminase (AID) [36]. Predicting that
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compared the patterns of SM for the same categories of MAb as
for CDR-H3 length in Table 1. For many comparisons, the
patterns observed for SMs paralleled those observed for CDR-H3
length. For example, the eight bNt HIV MAbs had both the
highest average CDRH3 length and the highest average level of
SM in VH (mean 53.3). Given the small number of bNt MAbs,
these were significantly longer than the non-bNt HIV MAbs
(mean 27.3, p=0.0024), but not when the Bonferroni correction
for multiple tests was used. In comparing MAbs from the different
types of immune response, the ChI MAbs (SM mean 27.3) were,
again, most different from the AcI MAbs (mean 10.9), with the
SAD MAbs being intermediate (mean 17.9). The SAD and AcI
MAbs showed opposite patterns when they were partitioned
according to protein vs. non-protein Ag; for SAD, the SM level
among anti-protein MAbs was higher than that of MAbs against
non-protein Ags, whereas for AcI MAbs, the level of SM was lower
for protein vs. non-protein Ags. The average number of SMs for
AcI MAbs against non-protein Ags, which were mainly against
streptococcal capsular polysaccharide, was 15.5, intermediate
between ChI and SAD non-protein MAbs. However, the level
of SM was extremely low for AcI MAbs against protein Ags (mean
7.9), many of which were against rotavirus (more than 40%). This
reduction in SMs among the anti-protein AcI MAbs was not
restricted to anti-rotavirus MAbs, as when they were excluded
from the AcI MAb category, the anti-protein AcI MAbs still had a
low number of SMs (mean 7.3). In summary, there was a
significant difference between Abs from chronic and acute viral
infections, with the latter consistently having much shorter CDR-
H3s and far fewer SMs. Little difference in SMs was observed
between anti-protein Abs produced by chronic processes (ChI and
SAD); both had long CDR-H3s and high levels of SM, and both
involve persistent exposure to Ag.
To further analyze the relationship between CDR-H3 length
and levels of SM, the MAb dataset was divided into quartiles
according to CDR-H3 length, with the shortest quartile (S)
having lengths of 13 aa or less, the longest quartile (L) 19 aa or
more, and the two middle quartiles comprising the M class
(between 14 and 18 aa inclusive, Table 2). While the differences
in SM levels observed in Table 1B among the disease conditions
or types of Ag specificities generally held across the corresponding
quartiles in Table 2, some differences were observed. Table 2B
Table 1. Comparison of CDR-H3 length, SM and distance from DH of VH genes among MAbs of known Ag specificity associated
with HIV infection (Table 1A), chronic infection (ChI), acute infection (AcI) or systemic autoimmune disease (SAD) (Table 1B), and
self vs. non-self (Table 1C).
MAb Type
a # MAbs CDR-H3 (aa) p
b # MAbs VH SM p # MAbs VH Distance
c p
All 427 16.3 -- 426 21.0 -- 413 445 --
A. HIV bNt 8 20.9 0.0501 8 53.3 0.0024 8 303 0.0541
HIV Non-bNt 185 17.7 184 27.3 167 508
HIV/P 192 17.8 0.2095 191 28.2 0.0209 181 503 0.0952
Non-HIV/P 34 16.5 34 21.0 32 440
B. ChI 227 17.6 0.0001 A 226 27.3 0.0001 A 214 492 0.0001
AcI 113 14.7 B 113 10.9 B 112 414 B
SAD 87 15.1 B 87 17.9 B 86 369 B
ChI/NP 1 16.0 0.5140 1 60.0 0.0836 1 286 0.6627
AcI/NP 43 14.0 43 15.5 43 357
SAD/NP 60 15.0 60 13.2 60 379
ChI/P 226 17.6 0.0001 A 225 27.1 0.0001 A 204 493 0.0018 A
AcI/P 70 15.1 B 70 7.9 B 69 450 A/B
SAD/P 27 15.4 B 27 28.5 A 26 346 B
C. Self 87 15.1 0.0031 87 17.9 0.0370 86 369 0.0003
Non-self 340 16.6 339 21.8 327 466
NP 104 14.6 0.0001 104 14.6 0.0001 104 369 0.0001
P 323 16.9 322 23.1 309 471
Self/NP 60 15.0 0.3519 60 13.2 0.0001 60 379 0.6206
Self/P 27 15.4 27 28.5 26 346
Non-self/NP 44 14.0 0.0001 44 16.6 0.0148 44 355 0.0001
Non-self/P 296 17.0 295 22.6 283 482
aMAbs are categorized by Ag type and condition: bNt, broadly neutralizing; NP, non-protein; P, protein; SAD, autoimmune disease; ChI, chronic infection; AcI, acute
infection and vaccination; Self = SAD MAbs; non-Self = ChI plus AcI MAbs.
bDifferences between means were analyzed by the Kruskall-Walis Test (PROC NPAR1WAY, SAS), and the uncorrected p values are shown. This analysis involved testing 9
groupings of MAbs (e.g. HIV bNt vs. HIV Non-bNt) for 3 parameters (CDR-H3 length, SM, and distance of VH gene from VH6-1), or 27 tests of heterogeneity among sets
of MAbs. Therefore the critical value adjusted for multiple tests (i.e., bonferroni correction, see Materials and Methods) was 0.05/27 =.0019; all p values satisfying this
corrected level of significance are shown in bold). When the Kruskall-Wallis test showed significant heterogeneity among 3 categories of MAb being compared (i.e., ChI,
AcI and SAD), we used parametric, a posteriori Tukey pair-wise comparisons (PROC GLM, SAS) to determine which sets of MAbs were contributing to the heterogeneity.
For this Tukey a posteriori test, letters denote conditions that differ at the 5% level. For example, ChI, AcI and SAD Abs were heterogeneous for CDR-H3 length at the
p,0.0001 level according to the Kruskall-Wallis test, and the Tukey a posteriori test grouped AcI and SAD Abs together (letter B), but different from ChI Abs (letter A).
cDistance between an Ab’s germline VH gene and the VH6-1 gene, the VH gene closest to the DH region.
doi:10.1371/journal.pone.0016857.t001
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protein Abs for all disease categories and little difference in SM
levels between the quartiles for medium-length and the longest
CDR-H3s; however, the short CDR-H3 quartile tended to have
lower levels of SM than did the longer two groups. Furthermore,
the trend for MAbs against non-protein Ags was reversed: MAbs
in the shortest CDR-H3 quartile tended to have the highest SM
levels for both the SAD and AcI categories. Although long CDR-
H3 MAbs against non-protein Ags are uncommon, their SM level
was lower than that of their short CDR-H3 counterparts. This is
consistent with the hypothesis that MAbs against non-protein Ags
(even those with long CDR-H3s) may derive from different B-cell
subsets and/or different immune processes than the MAbs
against protein Ags.
Germline VH-gene usage in adaptive Ab responses
Early reports of VH gene family usage in anti-HIV Abs reported
that VH3 was over-utilized and VH4 was under-utilized compared
to the naı ¨ve repertoire [37,38]. Given that our dataset includes
Abs of known Ag specificity for several disease conditions, we
compared the use of V-gene families and of the specific gene VH1-
69 among these conditions (Table 3 and Figure S1). Table 3
shows that there were significant differences when the proportions
were tested across each gene family. The proportion of anti-HIV
MAbs that use family VH3 genes (29%) was lower than that for
SAD MAbs (52%) or AcI MAbs (53%). Concomitantly, use of
family VH1 increased for HIV MAbs (38% for HIV compared to
23% for SAD MAbs and 22% for AcI MAbs), whereas the
proportion of MAbs using family VH4 was not significantly
different among the major categories, ranging from 18 to 25%.
Thus, HIV infection was related to an increase in VH1 and
decrease in VH3 gene usage that was not apparent for ChI Abs
(perhaps because this sample size is small) or other conditions.
We were particularly interested in usage patterns for the VH1-
69 germline gene, as it is not commonly used in the naı ¨ve
repertoire (e.g., Wardemann et al. 2003 [39]), but is characteristic of
Ab repertoires in several disease states (see Discussion). As shown
in Table 3, analysis of the 193 HIV MAbs having verifiable
germline VH genes revealed that 43 (22%) used VH1-69, whereas
only five of 87 (6%) SAD MAbs and three of 113 (3%) AcI MAbs
used this VH gene; VH1-69 usage by (non-HIV) ChI MAbs was
intermediate, being four of 34 (12%). Thus, HIV MAbs, and,
perhaps, ChI MAbs use VH1-69 at a higher frequency than do
SAD or AcI MAbs.
Given this distinct difference, we directly compared the features
of MAbs that use VH1-69 to those that do not (Table 4). Among
ChI MAbs, those that used VH1-69 had significantly longer CDR-
H3s (means of 20.1 vs. 17.0, P,0.001), whereas their SMs were
not significantly different. Very few SAD or AcI MAbs used VH1-
69, so no statistical comparisons could be made within those
groups. Among MAbs that use VH genes other than VH1-69, the
patterns among the disease categories of ChI, SAD and AcI were
similar to those observed in the full data set; the CDR-H3 length
of ChI MAbs remained significantly longer than those of SAD and
AcI MAbs, and the SMs of all three groups were different. Thus,
ChI Abs encoded by VH1-69 appear to have longer CDR-H3s but
not more SMs than their counterparts that do not use this
germline gene.
VH1-69 is a fairly distal gene, being approximately 764 Kb from
VH6-1 [40]; only five of the approximately 40 functional VH-genes
are more distal. Thus we wondered if the use of VH1-69 among
Abs bearing long CDR-H3s in HIV infection could be part of a
Figure 1. Distribution of CDR-H3 length for HIV Mabs. HIV Mabs are divided into three categories: bNt HIV MAbs, all HIV MAbs with the bNt
HIV MAbs removed (i.e., non-bNt HIV MAbs), and ChI MAbs with the HIV MAbs removed (i.e., non-HIV ChI MAbs). Arrows indicate the mean for each
category. Distribution of CDR-H3 length for more than 4000 Abs compiled from IMGT and Kabat databases [63] is included in Figs. 1–3, as a control
comparison (blue line). The average CDR-H3 length of the 425 Ag-specific MAbs was 16.3 aa, which is higher than the 15.2-aa mean reported for 4751
expressed VH sequences compiled from the Kabat and IMGT databases by Zemlin et al. [63]; this may reflect that our data set included a higher
proportion of ChI Abs, both HIV and non-HIV.
doi:10.1371/journal.pone.0016857.g001
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that ChI MAbs use the most distal VH genes, consistent with this
class having the longest CDR-H3s and the highest frequency of
SMs. However, inconsistent with CDR-H3 length and SMs, anti-
protein (anti-viral) AcI Abs had intermediate VH gene distances
whereas SAD Abs had the most proximal ones. Importantly, the
AcI MAbs, only three of which use VH1-69, used distal genes
overall; the average distance for 69 anti-protein (antiviral) AcI
MAbs is 450 kb, suggesting that distal genes besides VH1-69 may
be selected in viral infections of all types.
Table 2 further analyzes the relationship between CDR-H3
length and VH gene distance, dividing the MAbs into short,
medium and long. Table 2 shows that the pattern is also not
consistent within disease condition. Analyzing CDR-H3 length by
quartile, the trend between CDR-H3 length and VH gene
distance held for ChI and SAD but not for AcI Abs. The medium
and long quartiles of ChI and SAD MAbs used the most distal
VH genes, whereas they were used by the short and medium
quartiles of anti-protein AcI MAbs. Thus, within the viral
infection groups, and following similar trends for SM, distal gene
usage was related to CDR-H3 length for the ChI, but not the
AcI, MAbs.
Discussion
The primary motivation for this analysis was to determine if
other types of Ab share features with the bNt HIV MAbs, which
might help explain the rarity of bNt MAbs in HIV-1 infection. We
found that the bNt MAbs most closely resemble the other anti-
HIV MAbs, and ChI MAbs as a group, in being enriched for long
CDR-H3s and high numbers of SMs; this indicates that these
features are not limited to broad neutralization, but appear to be
common characteristics of the Abs involved in chronic viral
infections. That all anti-HIV MAbs, including the bNt MAbs,
share similar features indicates that unusual immunological
processes, such as breaking of tolerance [19], are probably not
responsible for the rarity of the bNt Abs during chronic HIV
infection. Instead, processes involved in chronic viral infections in
general may be at play in shaping the repertoire of Abs available
for selection after viral persistence and/or multiple rounds of viral
escape; such processes are probably linked to broadening of the Ab
response beyond those involved in the response to initial infection
[41]. Our results are consistent with the view that Abs having the
features of the bNt MAbs are not rare, but arise as a result of
chronic viral infection.
Strikingly, the Abs from acute viral infections (anti-protein AcI
Abs) had significantly shorter CDR-H3s and lower numbers of
SMs than did the ChI Abs. In addition, while both types of Ab
tended to use distal VH genes, Abs from acute viral infections
bearing long CDR-H3s tended not to use the most distal VH
genes, nor did they use VH1-69 to the same extent as the ChI (and
HIV) Abs. We speculate that, if the Abs involved in acute viral
infections reflect those produced during the early phases of chronic
viral infection, a shift in expressed VH gene composition (i.e.,
CDR-H3 length and VH gene usage) must occur over time, along
with an increase in SMs.
Figure 2. Distribution of CDR-H3 length for HIV MAbs against the different sites on Env. Env sites are categorized as: CD4bs, CD4i, V3
loop, gp41, and control MAbs (blue line) [63]. Arrows indicate the mean for each category.
doi:10.1371/journal.pone.0016857.g002
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PLoS ONE | www.plosone.org 5 March 2011 | Volume 6 | Issue 3 | e16857Figure 3. Distribution of CDR-H3 length for different types of immune response and Ag type. A. Distribution of CDR-H3 length for ChI,
SAD, and AcI MAbs. B. Distribution of CDR-H3 length for ChI anti-protein, SAD anti-protein, AcI anti-protein, SAD anti-non-protein, and AcI anti-non-
protein MAbs. Arrows indicate the means for each category. Control MAbs (blue line) are included for comparison [63].
doi:10.1371/journal.pone.0016857.g003
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were also found among SAD-related anti-protein MAbs. This lack
of shared features between the SAD and bNt MAbs (or ChI MAbs
in general) suggests that the bNt MAbs against HIV are probably
not drawn from an initial pool of autoimmune B cells bearing long
CDR-H3s, as previously hypothesized [19,20,42]; were that the
case, then the bNt MAbs would be expected to be similar to the
SAD MAbs but not the ChI ones. Clearly, Abs having the features
of the bNt MAbs are not rare, and are routinely produced during
ChIs. Thus, it seems more likely that the rarity of the bNt HIV
Abs results from the cryptic, flexible and/or transient nature of
conserved epitopes on the neutralization-competent structure of
HIV Env; such epitopes are not immunodominant on the virus,
nor on the envelope ‘‘debris’’ shed by infected cells, and as such,
multiple rounds of viral escape are likely required before the
immune system can mount an effective Ab response against them.
This study is to our knowledge the first to explicitly compare
gene family usage in MAbs from HIV with those from other types
of immune response. We observed a bias toward family VH1 and
against family VH3 genes in the HIV and other ChI MAbs. The
increased usage of family VH1 agrees with Scheid et al. [43]; and
removal of the large number of Abs from Scheid et al. did not affect
this conclusion (analysis not shown). A deficit in family VH3 usage
associated with HIV infection has been reported in several studies
[37,38,44,45,46]. This deficit is consistent with the suggestion that
HIV-1 gp120 acts as a superAg that specifically deletes B cells
bearing Abs encoded by genes from family VH3 [47,48]. In
addition, and in contrast to some previous findings [45], we did
not observe over-utilization of the VH4 family, which remained
mostly constant across all MAb categories.
We observed an overabundance of VH1-69 gene usage in the
HIV MAbs and among ChI MAbs in general, compared to the
naı ¨ve repertoire reported from other studies [39], and to the
other MAb categories in our database. Our results extend the
Table 2. Somatic mutations and VH-gene distance of MAbs
grouped according to short (,=13aa), medium (14-18 aa) or
long (.=19aa) CDR-H3 length.
MAb Typea VH SM VH Distance
b
SM L S M L
All 16.5 21.8 22.9 353 466 488
A. HIV bNt NA
c 76.5 (2)
d 45.5 (6) NA 286 (2) 320 (6)
B. ChI 24.1 27.9 26.1 327 498 539
AcI 10.6 11.5 8.9 (15) 401 448 322 (15)
SAD 16.5 18.9 17.7 (14) 299 405 394 (14)
ChI/NP NA 60.0 (1) NA NA 286 (1) NA
ChI/P 24.1 28.2 26.9 333 504 534
HIV/NP NA 60.0 (1) NA NA 286 (1) NA
HIV/P 25.3 29.7 27.3 334 517 537
Not HIV/NP NA NA NA NA NA NA
Not HIV/P 19.0 (6) 19.6 (16) 24.0 (12) 328 (6) 424 (14) 516 (12)
AcI/NP 15.8 (19) 15.6 (21) 14.3 (3) 329 (19) 400 (21) 229 (3)
AcI/P 6.1 (22) 9.2 7.6 (12) 466 (21) 476 346 (12)
SAD/NP 15.0 (22) 11.9 12.8 (10) 327 (22) 402 429 (10)
SAD/P 22.0 (6) 30.4 (17) 30.0 (4) 197 (6) 411 (16) 307 (4)
C. Self 16.5 18.9 17.7 (14) 299 405 394 (14)
Non-self 16.4 22.6 24.3 375 483 502
NP 15.4 14.4 13.2 (13) 328 399 382 (13)
P 17.2 24.1 24.8 370 488 502
Self/NP 15.0 (22) 11.9 12.8 (10) 327 (22) 402 429 (10)
Self/P 22.0 (6) 30.4 (17) 30.0 (4) 197 (6) 411 (16) 307 (4)
Non-self/NP 15.8 (19) 17.6 (22) 14.3 (3) 329 (19) 395 (22) 229 (3)
Non-self/P 16.6 23.3 24.6 392 497 510
aMAbs are categorized by Ag type and condition: Nt, broadly neutralizing; NP,
non-protein; P, protein; SAD, autoimmune disease; ChI, chronic infection; AcI,
acute infection and vaccination; Self = SAD MAbs; non-Self = ChI plus AcI
MAbs.
bDistance between an Ab’s germline VH gene and the VH6-1 gene, the VH gene
closest to the DH region.
cNA, Not available; i.e., there were no MAbs of this type in the database.
dSample sizes,25 are given in parentheses.
doi:10.1371/journal.pone.0016857.t002
Table 3. VH gene family and VH1-69 gene usage among 4
types of MAbs.




HIV % SAD % AcI
A.
c VH-1 39 (76)
c 21 (7) 23 (20) 22 (25) **
VH-2 2( 3 ) 0( 0 ) 1( 1 ) 0( 0 ) N S
VH-3 29 (56) 44(15) 52 (45) 53 (60) **
VH-4 24 (47) 26 (9) 18 (16) 23 (26) NS
VH-5 6 (11) 9 (3) 5 (4) 1 (1) NS
VH-6 0( 0 ) 0( 0 ) 1( 1 ) 1( 1 ) N S
Total 100 (193) 100 (34) 100 (87) 100 (113)
Specific Gene
B.
d VH1-69 22 (43) 12 (4) 6 (5) 3 (3) **
aNS, Not significant;
**p,0.001.
bFor each VH gene family (row), the proportion of MAbs using that gene family




cData are presented as per cent followed by number of MAbs in parentheses.
dProportion of MAbs using the VH1-69 gene was also tested for heterogeneity
among the four sets of MAbs.
doi:10.1371/journal.pone.0016857.t003
Table 4. Association between VH1-69 gene usage, CDR-H3
length and number of somatic mutations.
Condition CDR-H3 length VH gene SM
VH1-69 Not VH1-69 Tt VH1-69 Not VH1-69 Tt
b
ChI 20.1 (47)**
a 17.0 (180) A
b 27.6 (47) NS 27.2 (179) A
AcI 15.3 (3) 14.7 (110) B 14.7 (3) 10.7 (110) B
SAD 15.2 (5) 15.1 (82) B 31.2 (5) 17.1 (82) C
aMean (# of MAbs). CDR-H3 length and SM were tested between ChI MAbs
using VH1-69 and those that do not; CDR-H3 length was significantly different
(p,0.001), while the average number of SMs was not different (NS). Statistical
comparisons were not made between SAD and AcI MAbs due to the low
numbers of those MAbs using VH1-69.
bTt, Tukey test. Letters denote conditions (rows) that differ at the 5% level in a
posteriori comparisons among MAbs not using VH1-69. Again, statistical
comparisons were made only for those not using VH1-69, due to the low
numbers of SAD and AcI MAbs that used VH1-69.
doi:10.1371/journal.pone.0016857.t004
Comparison of Antibody Repertoires
PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e16857observations of Huang et al. [49], who noted that nine of twelve
MAbs against the CD4i site of gp120, used VH1-69, and those of
Gorny et al. [46], who showed that MAbs against all HIV Env
epitopes, except the V3 loop, are enriched for VH1-69 usage. In
addition, three studies have noted almost exclusive use of VH1-69
among cross-protective MAbs against influenza virus [50,51,52].
Both AcI and ChI MAbs tended to use distal VH genes, but only
in the latter group were long CDR-H3s present in Abs encoded by
distal VH genes, which tended to be VH1-69. Three mechanisms
can produce long CDR-H3s: (i) longer VH,D H,o rJ H genes can be
used preferentially, (ii) CDR-H3 can be lengthened by insertions
induced by activation-induced cytidine deaminase [9,53], and (iii)
secondary rearrangement (or receptor editing or revision [54,55])
can result in N and P additions at the N1 junction. Secondary VH-
gene rearrangement necessarily involves the use of distal VH and
JH genes, because once a VH gene is somatically recombined with
aD H gene (i.e., after primary V-D-J rearrangement), only genes
more distal to the DH region are available for further joining. The
features of the ChI Abs alone are consistent with secondary
rearrangement model, in both using distal VH genes and having
long CDR-H3s for the same Ab population. Thus, viral infection
appears to select for distal VH genes, but if secondary rear-
rangement is playing a role in lengthening CDR-H3, it appears to
be doing so only for the ChI Abs.
Many of our conclusions should be interpreted with caution,
given that they are based on a limited dataset that may be biased
in several ways. For example, there was significant bias related to
Ag specificity for several categories of MAb; many of the anti-HIV
MAbs were against the gp120 CD4bs, and were obtained via
phage-displayed Ab libraries; most of the SAD MAbs were against
the non-protein Ags DNA and phospholipid/cardiolipin; whereas
most of the AcI MAbs were against streptococcal capsular
polysaccharide and rotavirus. Another potential bias is related to
the limited number of SADs we studied, with the preponderance
being SLE and anti-phospholipid syndrome. Since we are studying
MAbs, it is important to realize that particular antibodies are often
selected for further study based on characteristics such as strength
of binding, isotype or epitope, and thus the data set is not random
with respect to these parameters. This is one reason why we
adopted a conservative approach, and emphasize those results that
satisfy a Bonferroni-adjusted p value based on the total number of
tests conducted in Table 1. A larger dataset, indexed by disease
and clinical condition, would overcome many of these potential
biases. One roadblock to such a compilation is that many
researchers do not routinely submit expressed sequences to public
databases; this will become especially critical as high-throughput
methods are employed to survey large sets of disease-specific
MAbs.
This analysis of 427 Ag-specific MAbs should directly inform
vaccine research. For example, the result that long CDR-H3s are
associated with chronic and persistent Ag and anti-protein Abs
motivates several questions. Are Abs bearing long CDR-H3s
present at the beginning of an immune response, or do they
‘‘evolve’’ over time? If they accumulate over time, then are they
directly selected from a pre-existing minor compartment within
the naı ¨ve B-cell populations, do they comprise a specially recruited
B-cell subset, and/or do they evolve by secondary processes (e.g.,
VH-gene replacement, DNA insertion, or gene conversion)? All of
the bNt MAbs against HIV are heavily mutated and five of the
eight have long CDR-H3s. This line of reasoning raises the
possibility that long CDR-H3s are not required to bind conserved
epitopes on the HIV-1 envelope, but arise instead through
processes that come into play during long-term persistence of
protein Ag and viral escape. If so, an effective HIV vaccine may
produce bNt Abs via "normal" immunization processes, by virtue
of enhancing the immunogenicity of Nt sites on Env. Given this
scenario, it remains unknown if Abs bearing the features of acute
antiviral Abs (which we expect to be similar to the features of Abs
elicited by a traditional vaccine) can act as bNt Abs. While bNt
Abs have yet to be elicited by vaccines meant to mimic the
epitopes on Env that mediate neutralization by the bNt MAbs,
that should not be taken as evidence that they cannot be so
produced. Our results indicate that HIV vaccine research should
continue to follow ‘‘reverse vaccinology’’ approaches [56] that
attempt to make the sites recognized by the bNt MAbs
immunodominant [57,58]. Progress in this approach has recently
been observed with an influenza vaccine that elicts broadly
protective Abs [59]. Conversely, it is also possible, but not proven,
that ‘‘chronic’’ type Abs bearing the features of the bNt MAbs will
be required for broad neutralization. If this is the case, then
research into the cellular and genetic origins of such Abs is
required. Thus our second recommendation is for research efforts
to be expanded in this area, with the goal of developing
vaccination strategies that stimulate key features of these chronic
processes, and in so doing, elicit bNt Abs.
Materials and Methods
Sequence database
Heavy chain sequences of expressed MAbs were retrieved from
the IMGT/LIGM-DB on-line database (http://imgt.cines.fr/),
from the literature, and from direct contacts with researchers (see
Table S1). Our goal was to collect VH sequences for all of the
available human HIV MAbs. The Ag targets of the HIV MAbs
included gp120, its CD4 binding site (CD4bs) and CD4 inducible
site (CD4i), the gp120 V3 loop, gp41, Rev, Tat, p24, and p25.
This MAb dataset was expanded to include human MAbs
associated with other chronic infections (the ChI MAbs), including
those against Epstein Barr virus, hepatitis B and C virus, herpes
simplex virus and human cytomegalovirus. (Note that all of these
MAbs are from viral infections.) For comparison, a similar group
of MAbs from Systemic Autoimmune Disease (SAD) was
assembled, including from systemic lupus erythematosus (SLE),
anti-phospholipid syndrome, mixed connective tissue disease,
rheumatoid arthritis, Sjo ¨gren’s disease, and cold agglutin disease,
and against the Ags, cardiolipin (serum dependent and serum
independent), phospholipids, DNA, beta-2-glycoprotein, Sm
ribonucleoprotiens, myelin basic protein, myelin-associated glyco-
protein, achetylcholine receptor, Ro/SSA and La/SSB. We
concentrated on SAD MAbs based on the hypothesis that the
bNt anti-HIV MAbs were derived from autoAb/autoreactive
precursors [19,20,42]. In addition, VH sequences were collected
for MAbs associated with acute infections (Pseudomonas aeruginosa,
rotavirus, Pneumococcus pneumoniae, Ebola virus, Neisseria meningitidis,
hepatitis A virus), and from vaccinated individuals (Haemophilus
influenzae Type b conjugate vaccine, 23-valent pneumococcal
polysaccharide vaccine, Streptococcus pneumonia, tetanus toxoid,
hepatitis B surface Ag), reported as the AcI MAbs. For each
MAb, we attempted to obtain information on its isotype, Ag
specificity, the methods used to obtain it (e.g., phage display, B-cell
sorting, etc.), clinical data on the source-subject, and the
bibliographic reference and GenBank accession number for the
original MAb sequence. This information was entered into an
Excel database by hand.
Sequence analysis
Nucleotide sequences were analyzed using a recent version
of JoinSolver (http://joinsolver.niams.nih.gov/index.htm; [60]),
Comparison of Antibody Repertoires
PLoS ONE | www.plosone.org 8 March 2011 | Volume 6 | Issue 3 | e16857which provides the closest-matched VH,D H and JH genes,
determines the limits of the CDR-H3 region, the length (in amino
acids) of CDR-H3 region, the contributions of P and N nucleotides
at both the V-D and D-J junctions, and the number of SMs in the
MAbs relative to the predicted germline genes (this number is
defined as of the number of base pair substitutions relative to a
predicted germline gene). These results, including nucleotide
sequence for CDR-H3 region, were also entered into the Excel
database. For a few HIV MAbs, only CDR-H3 length, and not the
expressed VH sequence, was available (e.g., Ditzel et al. [61]; see
Table S1). Results from JoinSolver were compared to those
produced by the V-QUEST and JunctionAnalysis algorithms of
the IMGT system [62], which also analyzes VH sequences for gene
usage and somatic mutations. In addition, assignments of each
MAb to predicted germline VH,D H and JH genes were confirmed
visually. Results from IMGT and JoinSolver differed systemati-
cally. For example, the size of the region of CDR-H3 contributed
by the germline DH gene was consistently estimated to be greater
using IMGT V-QUEST. This result can be explained by the fact
that standard parameters for V-QUEST allow more mutations in
the DH-gene core. However, differences between classes of MAbs
were similar whether the comparisons were calculated using V-
QUEST or JoinSolver, and these relative differences (e.g., the
average CDR-H3 length of self vs. non-self MAbs) are the
important parameters in our study.
JoinSolver results were used to screen for clonal expansions,
which were identified as those Abs that used the same sets of VH,
DH and JH regions with similar patterns of N and P nucleotides. A
single, randomly chosen MAb was retained to represent each
clonally-expanded set. Two recently reported bNt MAbs [7] are
expansions of the same B-cell lineage, so we randomly selected
one, PG16, for analysis; taking the same approach we selected
VRC01 from the set of two bNt MAbs reported by Wu et al. [9].
Thus, the final set that was statistically analyzed does not include
all reported HIV MAbs, but only those representing independent
clonal lineages (see below, and Tables S1 and S2).
In summary, the entire database consists of over 700 MAbs
(Table S1), which underwent two screens to produce the final
dataset (Table S2) for analysis of CDR-H3 length, SM and gene
usage. In the first screen, each MAb had to have a specified Ag,
and to be associated with a particular immune response. In the
second screen, clones from the same clonal expansion were deleted
from the dataset, resulting in a 427-MAb dataset comprising 227
ChI MAbs (including 193 HIV MAbs), 87 SAD MAbs and 113
AcI MAbs, which was exported to SAS (Rel. 8.2, 2001; SAS
Institute Inc., Cary, NC) for statistical analysis. Of these
427 MAbs, 318 were identified as to IgM or IgG; 90% of these
were IgG (Table S2).
Statistical analysis
For all MAb categories, PROC UNIVARIATE (SAS) was used
to test the distributions of CDR-H3 length, total VH-gene
mutations, distance of predicted VH gene used in the MAb
relative to VH6-1, the V-gene most proximal to the DH region
(VH-distance), and distance of predicted JH gene from JH6, the
JH gene most distal to the DH region (JH-distance), against the
normal distribution. Most of the distributions were non-normal,
even after log transformation, so a non-parametric Kruskall-Wallis
Test was used to test for differences among sets of MAbs (PROC
NPAR1WAY, SAS). To avoid zero values, the natural log of
(3*CDR-H3 length in aa + 0.1) was used in tests for differences in
CDR-H3 length. All results from the non-parametric tests were
compared to one-way ANOVA (PROC GLM, SAS), and in all
cases the results were similar in terms of levels of significance.
When more than two categories were compared, (i.e., comparisons
among ChI, AcI and SAD MAbs), Tukey a posteriori tests were used
to determine what groups were statistically different, and these
different groups were denoted by different letters (PROC GLM,
SAS). In Table 1 we present the p values for the main statistical
tests of this study. This Table reports 9 hypothesis tests for each of
CDR-H3 length, number of SMs and VH-distance, for a total of
27 tests; therefore, to be conservative, all tests that passed a
Bonferroni-corrected P value of 0.05/27=0.0018 were highlight-
ed in bold. Given the many confounding factors in this data base,
these probability values should be interpreted as indicators of
strong differences among categories rather than strictly interpreted
statistical tests (see Discussion). Distributions of CDR-H3 length
for CD4bs, CD4i, V3 loop, and anti-gp41 MAbs presented in
Figure 2 were tested for heterogeneity by x
2.J H-distance did not
vary among MAb categories and is not reported. The difficulty of
assigning germline DH genes to expressed Ab sequences, especially
for highly mutated HIV MAbs, precluded a comprehensive
analysis of DH gene usage or the number of P and N nucleotides.
Supporting Information
Figure S1 VH gene family usage in anti-protein and non
anti-protein MAbs for 3 disease conditions. See Table 3 for
sample sizes; there is only 1 ChI Mab that is not anti-protein.
MAbs utilizing VH1 family were separated into those using VH1-
69 and others.
(TIF)
Table S1 Database of antigen-specific expressed human MAbs.
(XLS)
Table S2 Expressed MAbs analyzed for CDR-H3 length,
somatic mutations, and gene usage.
(XLS)
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